Trial Profile
An observational, prospective study to evaluate outcomes in patients treated with first line therapy with Imatinib and than switched to second line therapy with Nilotinib and Dasatinib:an extension study of EUTOS study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2017
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 27 Jul 2017 New trial record